CA
NZ
UK
AU
IND
US
HUTCHMED Limited(NASDAQ:HCM)announced renewed inclusion of three key oncology therapies—ELUNATE®, ORPATHYS® and SULANDA®—in China’s updated National Reimbursement Drug List (NRDL), effective January 1, 2026. The renewed listing follows a contract renewal with the National Healthcare Security Administration, reflecting continued recognition of these therapies within China’s …
Structure Therapeutics (NASDAQ:GPCR) announced that it will publish topline results from its ACCESS clinical program evaluating aleniglipron, the company’s once-daily oral GLP-1 receptor agonist for obesity, before the market opens on December 8, 2025. Anticipation is high as the company works to advance an …
Immix Biopharma (NASDAQ:IMMX) announced promising Phase 2 clinical results for its sterically optimized CAR-T candidate NXC-201 during an oral presentation at ASH 2025. Led by Dr. Heather Landau of Memorial Sloan Kettering Cancer Center, the data highlighted a 75% complete response rate in relapsed/refractory …
Eli Lilly and Company (NYSE:LLY) has released pivotal data from the Phase 3 BRUIN CLL-314 trial, marking the first randomized head-to-head comparison between covalent and non-covalent BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma. Jaypirca (pirtobrutinib), Lilly’s highly selective, reversible BTK inhibitor, …
Rigel Pharmaceuticals (NASDAQ:RIGL) presented updated data from its ongoing Phase 1b study evaluating R289, an oral prodrug of the dual IRAK1/4 inhibitor R835, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome. The findings were shared during an oral session at the 67th …
Incyte (NASDAQ:INCY) has announced that the U.S.FDAhas granted Breakthrough Therapy designation to INCA033989, the company’s first-in-class monoclonal antibody designed to target mutant calreticulin (mutCALR). The designation applies to patients with essential thrombocythemia who carry a Type 1 CALR mutation and are resistant or intolerant …
Prime Medicine (NASDAQ:PRME) has unveiled high-impact clinical results for PM359, its investigational autologous hematopoietic stem cell therapy for p47phox chronic granulomatous disease. The data represents the first clinical demonstration of Prime Editing in humans, signaling a potentially transformative step forward for gene-repair technologies.
Sprinklr, Inc. (NYSE:CXM)provides enterprise software for customer-facing functions. Its AI-enabled Unified Customer Experience Management (Unified-CXM) platform supports service, marketing, and other front-office teams by connecting workflows across departments, enabling engagement across digital channels, and using AI insights to manage customer interactions.
Market Movers (Yesterday):Capricor Therapeutics, Inc. surged 371.07%, leading the gainers, followed by iRobot Corporation which jumped 73.85%. Acrivon Therapeutics and several other small-cap biotech names also rallied sharply on short covering and FDA-driven optimism. On the downside, WORK Medical Technology Group Ltd fell 35.94%, …
Franklin Resources, Inc. (NYSE:BEN) is currently covered by TD Cowen with a Buy recommendation. Analyst Bill Katz initiated coverage on December 3, 2025. TD Cowen has assigned a price target of USD 31.00.
Please wait processing your request...